

Y90 SIRT with Occlusafe Micro-Balloon Catheter infusion system in a patient with unresectable HCC: the right way

Physician: Giulio Eugenio Vallati MD

Location: Department of Radiology and Interventional Oncology, Regina Elena National Cancer Institute, Rome, Italy



CLINICAL CASE

A 67-years-old man with no history of liver disease presented with 4 months of abdominal pain and weight loss. Abdominal CT showed a large hepatic lesion in the left lobe (74 x 57 x 46 mm) with portal vein bifurcation invasion. The CT characteristics of this lesion were suggestive for HCC (diagnosis confirmed with biopsy). The nodule was suitable for SIRT treatment.



CT before treatment documented a large and infiltrative hepatic mass in the left lobe with portal vein and biliary segmentary bile ducts invasion.

PROCEDURE


Through a right common femoral arterial access we performed celiac trunk catheterization (GLIDECATH® Hydrophilic Coated Catheter Simmons 2 -Terumo, Japan). Angiography showed no vascular abnormalities, with vascular supply to the lesion through the left hepatic artery. The first session of treatment ended with embolization of the upper gastro-duodenal artery with coils. The second session of treatment started with catheterization of common hepatic artery and super-selective catheterization of the left hepatic artery with Radiofocus® Guidewire GT and Occlusafe® micro-balloon catheter (Terumo, Japan). After Occlusafe® balloon inflation we performed SIRT treatment with injection of Y90-microspheres.



Y90-spheres infusion after upper gastro-duodenal artery embolization and inflation of Occlusafe micro-balloon catheter.

FOLLOW UP/ CONCLUSION

A SPECT-CT was performed soon after SIRT and confirmed the expected distribution of Y90-microspheres and the absence of non-target uptake. The Abdominal CT performed 3 months after treatment documented a tumor necrosis estimated to comprise more than 70% of initial tumor lesion.



On the left: exam after treatment with a good spread of Y90-spheres in the lesion, without non-target uptake. On the right: good response CT at 3 months after treatment.

PRODUCTS USED

Glidecath® Hydrophilic Simmons 2, Guidewire® M 0.035", Occlusafe® micro-balloon catheter; Guidewire® GT wire 0.014"; SIRT with Sir-Spheres® (1.8 GBq (SIRTEX, Australia)).

Occlusafe is not available for sale in all countries. Please contact your Terumo local sales representative for more information. Occlusafe has not been approved by the FDA and is therefore not available for sale in the U.S.A.

<https://www.terumo-europe.com/en-emea/Treat-liver-cancer-with-Terumo-2018>

byagency

PUSHING BOUNDARIES

